On Monday, Trupanion hit an important technical milestone, with its Relative Strength (RS) Rating rising into the 80-plus percentile with an upgrade to 80, a rise from 70 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks typically have an RS Rating north of 80 as they launch their biggest price moves.
Trupanion is now considered extended and out of buy range after clearing a 36.66 buy point in a first-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Trupanion posted 0% earnings growth in the latest quarterly report, while sales growth came in at 12%.
Trupanion holds the No. 3 rank among its peers in the Insurance-Accident & Healthcare industry group. Unum Group is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
